Skip to main content

BC Cancer – Prince George

If you are interested in more information about a particular trial, please speak with your treating physician first, and they may contact this centre for further information if necessary.

Tumour Group / Site

Trial Title/Summary

Opening Date

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors: A randomized phase II trial (SABR-COMET).

The purpose of this study is to assess the impact of stereotactic ablative radiotherapy on overall survival and quality of life in patients with metastatic cancer lesions in comparison to the standard of care treatment.

Status: On follow-up of accrued patients

Jun 2016

Phase II non-randomized trial of stereotactic ablative radiotherapy for oligometastases (SABR - 5).

The purpose of this study is to assess the quality of life and side effects in patients with metastatic cancer lesions who are being treated with a comprehensive oligometastatic SABR treatment program.

Status: Actively accruing patients

Jan 2017


A prospective cohort study evaluating risk of local recurrence following breast conserving surgery and endocrine therapy in low risk Luminal A breast cancer (LUMINA).

The purpose of this study is to determine whether Luminal A subtype breast cancer combined with other factors, such as tumour size and extent of disease, can identify a patient as having very low risk for reoccurrence following breast conserving surgery, and therefore not needing radiation therapy after breast conserving surgery. 

Status: On follow-up of accrued patients

Apr 2014

Biology of Breast Cancer

The purpose of this study is to maintain a repository of blood and tissue samples to support research in identifing how breast cancer begins, determining why breast cancers behave differently in some Individuals compared to others, and to learn more about treating breast cancer including positive and negative effects of various types of treatment. 

Status: Actively accruing patients
Oct 2016

Improving Quality of Life (QOL) after optimal radiotherapy for intermediate and high risk prostate cancer: HDR vs. LDR brachytherapy boost (QOL - HDR vs LDR).

The purpose of this study is to compare the quality of life in prostate cancer patients treated with low dose rate (LDR) brachytherapy in comparison to high dose rate (HDR) brachytherapy.

Status: Actively accruing patients

Sep 2014

Androgen suppression with stereotactic body or external beam radiation therapy: A phase II randomized trial for intermediate and high risk prostate cancer (ASSERT).

The purpose of this study is to compare the rates of acute and late toxicities of stereotactic ablative radiotherapy with conventional external beam radiation, as well as determine what proportion of potential participants will agree to participate and be randomized.

Status: Actively accruing patients

Mar 2017

Predictive Biomarkers in Genitourinary (GU) Cancers

The purpose of this study is to maintain a repository of blood and urine samples for all GU cancers. These samples will be used in the research of predictive biomarkers, mechanisms of resistance to various systemic therapies, and optimal treatment selection and sequencing at the Vancouver Prostate Centre or at other organizations involved in collaborative projects within BC Cancer. 

Status: Actively accruing patients
Oct 2017
Biology of Lymphoid Cancer

The purpose of this study is to maintain a repository of blood samples for all types of lymphomas. These samples will be used in research investigating causes, optimal treatments, and the effects treatments may have on these cancers.

Status: Actively accruing patients
Nov 2015
A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer. 

SABR-COMET-3 Status: Actively accruing patients


SOURCE: BC Cancer – Prince George ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2022 Provincial Health Services Authority